secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001558370-24-015149
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Phase 3 SAPPHIRE trial meets primary endpoint; Q3 net loss $64.5M
------------------------------------------------------------------------------

- Phase 3 SAPPHIRE achieved primary endpoint: apitegromab 1.8-point HFMSE improvement (p=0.0192) vs placebo.
- Plans to submit BLA and MAA for apitegromab in SMA in Q1 2025.
- Phase 2 EMBRAZE trial (apitegromab + GLP-1 for obesity) fully enrolled; data expected Q2 2025.
- Completed upsized $345M public offering; proforma cash $463.5M extends runway into Q4 2026.
- Q3 2024 net loss $64.5M ($0.66/share) vs $42.4M ($0.53/share) in Q3 2023; no revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/0001558370-24-015149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer